- Home
- MED vs IPHA Comparison
MED vs IPHA Comparison
Compare MED & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- IPHA
- Stock Information
- Founded
- MED 1980
- IPHA 1999
- Country
- MED United States
- IPHA France
- Employees
- MED N/A
- IPHA N/A
- Industry
- MED Packaged Foods
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- IPHA Health Care
- Exchange
- MED Nasdaq
- IPHA Nasdaq
- Market Cap
- MED 187.3M
- IPHA 150.9M
- IPO Year
- MED N/A
- IPHA 2019
- Fundamental
- Price
- MED $15.48
- IPHA $1.95
- Analyst Decision
- MED Hold
- IPHA Strong Buy
- Analyst Count
- MED 1
- IPHA 1
- Target Price
- MED $17.00
- IPHA $11.50
- AVG Volume (30 Days)
- MED 204.6K
- IPHA 50.9K
- Earning Date
- MED 02-18-2025
- IPHA 03-20-2025
- Dividend Yield
- MED N/A
- IPHA N/A
- EPS Growth
- MED N/A
- IPHA N/A
- EPS
- MED 0.67
- IPHA N/A
- Revenue
- MED $674,475,000.00
- IPHA $36,202,722.00
- Revenue This Year
- MED N/A
- IPHA N/A
- Revenue Next Year
- MED N/A
- IPHA $101.65
- P/E Ratio
- MED $23.25
- IPHA N/A
- Revenue Growth
- MED N/A
- IPHA N/A
- 52 Week Low
- MED $14.88
- IPHA $1.29
- 52 Week High
- MED $56.52
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- MED 36.38
- IPHA 56.50
- Support Level
- MED $15.67
- IPHA $1.72
- Resistance Level
- MED $16.30
- IPHA $1.92
- Average True Range (ATR)
- MED 0.55
- IPHA 0.11
- MACD
- MED 0.09
- IPHA 0.02
- Stochastic Oscillator
- MED 25.16
- IPHA 89.74
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.